Related items

The Digital Networks Act (DNA) can help the EU build a more coherent connectivity framework for businesses operating across borders. Today, fragmented rules and complex compliance obligations continue to hold back innovation and Europe’s competitiveness.

To this end, the DNA must reduce – not add to – regulatory complexity, ensure legal certainty and avoid duplication with existing EU legislation. It should support investment in next-generation networks while avoiding duplication with existing EU frameworks. Clear scope will be essential to prevent unintended overlap with cloud, content delivery networks or private networks.

Read more on how the DNA can support Europe’s digital transition and long-term competitiveness.

Intel has called Ireland home since 1989, investing more than €30 billion and supporting 4,900 jobs. Alongside this long-term commitment, the company is helping strengthen local communities through its Signature Charity initiative. For the past 16 years, the Intel Foundation and Intel employees have selected a charity each year to support through volunteering and fundraising. In 2025, Intel Ireland chose Teach Tearmainn, the only organisation in County Kildare dedicated to supporting women and children experiencing domestic violence and abuse. Through fun runs, cycling events, a triathlon, a giving campaign, employee-led fundraising and recycling initiatives, Intel employees raised €80,000 for the charity – the company’s largest charity donation to date. These efforts show how long-term investment, employee engagement and community partnerships can help deliver meaningful support where it is needed most. Read the full story on Invested in Europe.

Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation. 

The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment. 

The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.